Search

everythinglearnresearchcommunity

for

Search:↓

A 17-year-old experienced significant hair loss after switching from topical to oral minoxidil and adding finasteride. The recommendation is to return to topical minoxidil and continue with finasteride or consider dutasteride.

Topical finasteride may reduce more scalp DHT but is seen as inconsistent and messy compared to oral finasteride. Users report mixed results with both forms, with some preferring oral for its convenience and consistent dosing, while others find topical effective but harder to apply.

A user shared progress pictures after 6 years of using finasteride, showing maintained hair with no regrowth. Suggestions included possibly adding minoxidil and switching to dutasteride for better results.

The conversation discusses topical androgen receptor blockers for hair loss, mentioning Clascoterone, Pyrilutamide, GT20029, and RU58841. Ketoconazole's effectiveness and application methods are also debated.

A 16-year-old experiencing hair loss seeks treatment advice. They decide to start with Serioxyl, Ketoconazole shampoo, and Eucapil, considering Minoxidil and Finasteride for later use.

Potential treatments for hair loss, including Minoxidil, finasteride, RU58841 and various upcoming pharmaceuticals, gene editing and cloning. It is suggested that a cure, if found, would be highly profitable due to the large number of people affected by hair loss globally.

A user who was able to get dutasteride for free with their insurance, and another user mentioning that finasteride is only covered if it is used for medical reasons.

The post argues for teenage use of finasteride to prevent hair loss, citing minimal side effects and personal success. Replies criticize the advice, highlighting potential developmental risks and questioning the safety of finasteride for teenagers.

The conversation discusses disappointment over only receiving a financial report from Cassiopea instead of trial results for Breezula/CB-03-01, a hair loss treatment. However, there is optimism as the company is advancing Breezula into Phase III trials for men, starting trials for women, and submitting an NDA for their acne product, Winlevi.

The conversation discusses Fevipiprant, an asthma drug that may block CRTH2 and potentially stop male pattern baldness (MPB) without inhibiting DHT. It also mentions the use of finasteride and dutasteride for hair loss.

The conversation is about finding online pharmacies to obtain tretinoin for hairline improvement, with suggestions including Amazon and nurx.com. Alternatives like adapalene are also mentioned.

The conversation lists hair loss treatments including finasteride, dutasteride, RU58841, pyrilutamide, breezula, and fluridil, and suggests ketoconazole as another option. Some users warn against using certain treatments like cyproterone acetate, bicalutamide, and spironolactone due to their strong anti-androgen effects and potential impact on masculinity.

A user shared their experience of hair loss progression after one year on dutasteride, expressing disappointment with no improvement and considering other treatments like RU58841. Other users offered mixed responses, some seeing no change, others suggesting the hair loss might have been worse without treatment, and discussing the role of testosterone and DHT in hair loss.

Tretinoin's effect on hair loss is debated; some say it improves minoxidil's effectiveness, while others claim it causes hair loss. Treatments discussed include tretinoin, minoxidil, finasteride, RU58841, and dermarolling.

PP405 shows promise in activating dormant hair follicles and increasing hair counts but lacks detailed efficacy data compared to minoxidil and finasteride. Opinions are mixed, with some optimism and skepticism about its effectiveness.

Doctors in Denmark and other countries often lack knowledge about hair loss treatments like Finasteride and Dutasteride, causing patients to seek prescriptions from multiple doctors or online. Some users report better experiences in countries like Brazil and Korea, where doctors are more informed and willing to prescribe these medications.

GT20026 is discussed as a potential treatment for hair loss that targets androgen receptors without affecting hormone levels, but it may not promote significant regrowth. It is expected to be available by 2028, with other treatments like Breezula and Clascoterone also mentioned.

Finasteride is not linked to a 60% risk of persistent sexual dysfunction; this figure applies only to those already experiencing sexual issues. Most users do not have side effects, and the study's methodology is criticized for selection bias.

Topical Clascoterone showed a 539% improvement in hair count compared to placebo, but its effectiveness and safety are debated. Users compared it to minoxidil and finasteride, with mixed opinions on its potential release in 2026 or 2027.

PP405 is a promising new hair loss treatment that may reactivate dormant hair follicles without side effects. It could surpass traditional treatments like minoxidil and finasteride if successful in further trials.

Switching from finasteride to dutasteride can cause significant hair shedding if done abruptly. It's recommended to overlap both treatments and gradually taper off finasteride to minimize shedding.

Dutasteride is considered safe for conception, with semen concentrations being too low to cause harm. Users discuss switching between dutasteride and finasteride, with some experiencing side effects like acne and heart issues, and advice is given to maintain a consistent treatment regimen.

A woman is concerned about her husband's hair thinning and researches treatments like finasteride and minoxidil. He decides against medication due to potential side effects and plans to shave his head if necessary.

Dutasteride is discussed as a treatment for young hair loss sufferers, with mixed experiences regarding side effects and effectiveness. Some users report positive results with Dutasteride, while others prefer Finasteride or Minoxidil due to fewer side effects.

FCE 28260 (PNU 156765), an under-explored 5α-reductase inhibitor, showcases promising results in research by Giudici et al., outperforming well-known treatments like Finasteride in reducing the conversion of testosterone to DHT. Its superior efficacy, demonstrated through lower IC50 values in both natural and human recombinant enzyme studies, suggests it could offer more effective management of DHT-related conditions. Additionally, its lower molecular weight hints at better potential for topical application, potentially offering advantages in treating conditions such as androgenic alopecia. Despite its potential, it has not advanced in development, possibly due to financial limitations, leaving its therapeutic prospects and side effect profile largely unexplored.

Post Finasteride Syndrome (PFS) is debated, with some users reporting severe side effects from finasteride, while others believe these effects are rare or psychosomatic. Treatments discussed include finasteride, minoxidil, and RU58841.

The user is experiencing severe hair shedding while on finasteride and plans to start using ketoconazole shampoo to address a greasy, waxy scalp buildup. They are seeking additional advice for managing hair loss.

User experienced hair thinning due to high cortisol and thyroid issues, along with insulin resistance. They are taking magnesium, zinc, vitamin D, calcium, and selenium as supplements.

Creatine may increase scalp DHT without affecting serum DHT, potentially speeding up male pattern baldness (MPB) for those genetically prone. Treatments mentioned include Minoxidil, finasteride, and RU58841.

The conversation is about someone who has been taking finasteride for hair loss without success, considering switching to dutasteride or giving up treatment. Suggestions include trying dutasteride, microneedling, infrared therapy, multivitamins, and high-concentration topical solutions combining finasteride and dutasteride.